AttendMe Owl Logo
AttendMe
Evidence Evolution
CardiologyCardiology

How This Evidence Evolved

Dual Antiplatelet Duration Post-PCI

Finding the sweet spot between ischaemia and bleeding

3.4

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The DAPT trial (2014) studied drug-eluting-stent recipients after 12 months of aspirin plus clopidogrel or prasugrel. It compared another 18 months of thienopyridine with placebo while aspirin continued. Extended treatment reduced stent thrombosis (0.4% vs 1.4%) but increased moderate or severe bleeding (2.5% vs 1.6%). These results raised the question of how to balance ischaemic and bleeding risks.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Shorter DAPT trials tested a switch to clopidogrel or ticagrelor monotherapy. STOPDAPT-2 found 1-month DAPT followed by clopidogrel noninferior and superior to 12-month DAPT for its composite endpoint. In TWILIGHT-ACS, ticagrelor alone after 3 months of DAPT reduced BARC 2, 3, or 5 bleeding in patients with NSTE-ACS: 3.6% versus 7.6% with continued aspirin. In TICO, net adverse clinical events at 1 year occurred in 3.9% versus 5.9% with ticagrelor-based 12-month DAPT.
Extension

Follow-up studies, subgroup analyses, and real-world validation

MASTER DAPT randomized high-bleeding-risk patients 1 month after stenting to stop DAPT or continue for at least 2 more months. At 335 days, abbreviated therapy was noninferior for net adverse clinical events and major cardiac or cerebral events, and reduced major or clinically relevant nonmajor bleeding (6.5% vs 9.4%; P<.001). This supports selecting DAPT duration in relation to bleeding and ischemic risk.
Now

Current standard of care and ongoing research directions

Trials support selected shorter-DAPT strategies. STOPDAPT-2 tested clopidogrel monotherapy after 1 month; TWILIGHT randomized adherent, event-free patients after 3 months of DAPT. Aspirin-free PCI from the outset and integration of DAPT and PRECISE-DAPT risk scores remain questions for individual tailoring.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How long should dual antiplatelet therapy last after a stent?+
The answer has evolved from a fixed 12-month standard to a personalised approach. STOPDAPT-2 tested clopidogrel alone after 1 month of DAPT; TICO and TWILIGHT-ACS tested ticagrelor alone after 3 months. These trials found less bleeding in their selected populations. Duration requires individual bleeding and ischaemic risk assessment.
What is P2Y12 monotherapy after PCI?+
In this strategy, ticagrelor continues after aspirin stops. In TWILIGHT-ACS, patients completed 3 months of DAPT before randomization. In NSTE-ACS, BARC 2, 3, or 5 bleeding over 12 months was 3.6% with ticagrelor alone versus 7.6% with aspirin plus ticagrelor. Ischaemic event rates were similar.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026